New antibody AP601 enters human trials for Hard-to-Treat cancers
NCT ID NCT07165067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new drug called AP601 in 36 people with advanced solid tumors that have not responded to standard treatments. AP601 is a bispecific antibody designed to target a protein called CD73 found on some cancer cells. The main goal is to find the safest dose and check for side effects, not yet to prove it works against cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AP601 (a bispecific antibody)
What this could lead to
If successful, this could point toward a new treatment option for people with solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. It is too soon to know if AP601 will effectively shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
NOT_YET_RECRUITINGWaratah, New South Wales, 2298, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Epworth HealthCare
RECRUITINGMelbourne, Victoria, 3121, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pindara Private Hospital
NOT_YET_RECRUITINGBrisbane, Queensland, 4217, Australia
Contact
Contact Email: •••••@•••••